Status:
COMPLETED
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
Lead Sponsor:
Peking University People's Hospital
Conditions:
Bone Cyst Aneurysmal
Pathological Fracture
Eligibility:
All Genders
12-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons ...
Detailed Description
Patients with primary ABC treated with perioperative denosumab in the Musculoskeletal Tumor Center of Peking University People's Hospital between January 2014 and December 2016 will be reported in thi...
Eligibility Criteria
Inclusion
- pathologically diagnosed with primary aneurysmal bone cyst
- lesions in axial skeletons (i.e. spine, pelvis) which are difficult to reach a satisfactory surgical margin, and surgery can lead to very high incidence of complications.
- pathological fracture
- recurrence cases
Exclusion
- metastases or multi-focal lesions
- malignancy
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03415477
Start Date
January 1 2014
End Date
December 31 2017
Last Update
January 30 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.